Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML
In Partnership With:
Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.
Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia (AML).
A study presented at the 2017 ASH Annual Meeting evaluated the safety, feasibility, and efficacy of the novel FLT3 inhibitor crenolanib in combination with standard chemotherapy for patients with AML up to 60 years old who are FLT3-mutant. Patients were enrolled onto the study if they were newly diagnosed and untreated.
When looking at these patients, the results showed that the addition of crenolanib to chemotherapy was safe and well tolerated, Wang says. Of the patients evaluated, 29 (72%) achieved a complete response (CR) after 1 cycle of induction with cytarabine/anthracycline and crenolanib. Additionally, 3 patients achieved a CR after re-induction or after treatment with high-dose cytarabine or hematopoietic stem cell transplant. The adverse events were not significantly different than expected, said Wang.
